Telmisartan, Amlodipine, And Indapamide

Introduction Overview

Generic Name

telmisartan, amlodipine, and indapamide

Brand Name

Widaplik

Dosage Form

tablet

Drug Class

Miscellaneous antihypertensive combinations

Pharmacokinetics

Absorption:
Widaplik, a fixed-dose combination of telmisartan, amlodipine, and indapamide, demonstrates distinct absorption profiles for each component. Telmisartan is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 0.5 to 1 hour, and an absolute bioavailability of approximately 42-58%. Food intake does not significantly affect telmisartan absorption. Amlodipine is well absorbed with an oral bioavailability ranging from 64% to 90%, reaching peak plasma levels between 6 to 12 hours post-dose; food does not significantly impact amlodipine absorption. Indapamide shows good oral absorption with peak plasma concentration occurring after 1.5 to 2 hours. The combination in Widaplik does not notably alter the absorption patterns of the individual drugs, enabling effective once-daily dosing.

Distribution:
After absorption, telmisartan exhibits extensive plasma protein binding (~99.5%), primarily to albumin and alpha-1 acid glycoprotein, with a volume of distribution approximating 500 liters, indicating significant tissue distribution. Amlodipine is highly protein-bound (~93%) and has a large volume of distribution (around 21 liters/kg), reflecting wide distribution into tissues, especially vascular smooth muscle. Indapamide also shows significant plasma protein binding (79-88%) and a volume of distribution of about 8-11 liters/kg. The extensive distribution of these drugs contributes to their sustained antihypertensive effects, allowing steady plasma concentrations with once-daily dosing.

Metabolism:
Telmisartan undergoes minimal hepatic metabolism primarily by glucuronidation via UGT enzymes to pharmacologically inactive acyl glucuronide metabolites. It does not involve significant cytochrome P450 metabolism, reducing potential for CYP-mediated drug interactions. Amlodipine is extensively metabolized in the liver via CYP3A4 to inactive metabolites. Indapamide is metabolized hepatically by cytochrome P450 enzymes to inactive compounds. The metabolism of the components in Widaplik does not appear to interfere with each other, allowing predictable pharmacokinetics.

Elimination:
Telmisartan has a terminal elimination half-life of approximately 24 hours, predominantly excreted via the bile into feces, with minimal renal excretion. Amlodipine has a long elimination half-life of about 30 to 50 hours, supporting once-daily dosing, and is primarily eliminated via hepatic metabolism and renal excretion of metabolites. Indapamide elimination includes renal excretion of unchanged drug and metabolites, with a half-life of approximately 14-25 hours. The combined elimination profiles facilitate once-daily administration for Widaplik, maintaining therapeutic plasma concentrations and stable blood pressure control.

Dosage Forms

Available Dosage Forms:
Widaplik is formulated exclusively as oral tablets, containing fixed-dose combinations of its three active ingredients. The available fixed-dose strengths are:
- 10 mg telmisartan / 1.25 mg amlodipine / 0.625 mg indapamide
- 20 mg telmisartan / 2.5 mg amlodipine / 1.25 mg indapamide
- 40 mg telmisartan / 5 mg amlodipine / 2.5 mg indapamide

Dosages for Adults and Adolescents:
Widaplik is indicated for once-daily oral administration in adults and adolescents requiring combination therapy for hypertension. Initial therapy typically begins with the lowest dose (10 mg/1.25 mg/0.625 mg) especially in elderly patients or those prone to sensitivity. Dose titration should occur based on clinical response every 2 weeks, increasing as needed to achieve target blood pressure, with a maximum dose of 40 mg/5 mg/2.5 mg once daily. Tablets are to be swallowed whole, without crushing or chewing.

Specific Patient Populations:
In elderly patients, initial dosing with the lowest strength combination (10 mg telmisartan/1.25 mg amlodipine/0.625 mg indapamide) is recommended to minimize hypotension or electrolyte disturbances. Patients with renal impairment should be cautiously monitored due to the indapamide component, which may affect electrolyte and water balance. Hepatic impairment may require dose adjustment due to amlodipine metabolism. Widaplik should be avoided in pregnancy due to risks of fetal harm. Dose adjustments should be individualized with close clinical monitoring for efficacy and safety.

Mechanism Of Action

Widaplik employs a synergistic triple mechanism targeting different physiological pathways to reduce hypertension effectively. First, telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to AT1 receptors on vascular smooth muscle and adrenal glands. This blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced sodium and water retention. Additionally, telmisartan acts as a partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ), modulating insulin sensitivity and glucose metabolism, which may confer additional metabolic benefits in hypertensive patients with comorbid diabetes or metabolic syndrome.

Second, amlodipine functions as a dihydropyridine calcium channel blocker, inhibiting L-type voltage-gated calcium channels predominantly in vascular smooth muscle cells. This inhibition decreases intracellular calcium concentrations essential for muscle contraction, leading to vasodilation of peripheral arteries and reduced peripheral vascular resistance. The vasodilatory effect improves blood flow and decreases cardiac workload, effectively lowering blood pressure and reducing angina symptoms.

Third, indapamide is a thiazide-like diuretic that acts primarily on the distal convoluted tubules of the nephron. It inhibits sodium and chloride reabsorption, promoting natriuresis and diuresis, decreasing plasma volume and cardiac output. Additionally, indapamide possesses vasodilatory properties independent of its diuretic effects, contributing to decreased peripheral vascular resistance. This multifaceted action supports sustained blood pressure reduction with potential improvements in arterial compliance and remodeling.

Collectively, Widaplik's components provide complementary antihypertensive effects by targeting intravascular volume, vascular tone, and neurohormonal regulation. Clinical studies demonstrate that this triple combination yields superior blood pressure control compared to dual combinations or monotherapy, with a tolerable safety profile. The blend of mechanisms also supports use in diverse hypertensive populations, including those with metabolic disturbances or resistant hypertension.

Pharmacological Actions

Angiotensin II receptor blockade by telmisartan leading to vasodilation and reduced aldosterone secretion.
Partial PPAR-γ agonism by telmisartan improving insulin sensitivity and glucose metabolism.
Calcium channel blockade by amlodipine resulting in peripheral arterial dilation.
Diuretic effect of indapamide increasing urinary sodium and water excretion.
Direct vasodilatory effects of indapamide independent of its diuretic properties.
Reduction of peripheral vascular resistance by combined pharmacologic actions.
Decreased cardiac preload and afterload contributing to blood pressure reduction.
Potential improvement of endothelial function and arterial compliance.
Synergistic antihypertensive effect from combined blockade of renin-angiotensin system and calcium channels plus diuresis.
Long half-lives of components allowing once-daily dosing and stable plasma levels.
Reduction of cardiovascular risk factors through blood pressure control.
Amelioration of hypertension-related target organ damage via sustained blood pressure lowering.
Modulation of fluid balance and electrolyte regulation through indapamide.
Decreased myocardial oxygen demand from vasodilation and blood pressure reduction.
Metabolic benefits associated with telmisartan’s PPAR-γ activity.

Therapeutic Or Clinical Uses

Treatment of essential hypertension to reduce elevated blood pressure.
Initial antihypertensive therapy in patients requiring multiple drug classes.
Reduction of cardiovascular morbidity and mortality due to hypertension.
Lowering risk of stroke and myocardial infarction in hypertensive patients.
Control of blood pressure in patients with insulin resistance or metabolic syndrome.
Management of hypertension where monotherapy has proven insufficient.
Use in elderly patients requiring low-dose combination therapy for blood pressure control.
Treatment in patients with fluid retention due to mild diuretic effect of indapamide.
Adjunct therapy in hypertensive patients with concomitant cardiovascular risk factors.
Sustained blood pressure reduction over 24-hour dosing interval.
Improvement of blood flow and vascular resistance via amlodipine component.
Use in patients intolerant to ACE inhibitors due to cough or angioedema.
Management of hypertension to prevent end-organ damage including renal and cardiac complications.
Alternative treatment in patients with borderline hypertension requiring careful titration.
Therapy tailored for patients with potential metabolic concerns due to telmisartan’s PPAR-γ effects.

Side Or Adverse Effects

Common dizziness due to blood pressure lowering effects.
Headache frequently reported, possibly related to vascular changes.
Fatigue and general malaise especially during initiation or dose escalation.
Nausea and gastrointestinal discomfort in some patients.
Hypotension especially after dose initiation or increase, causing light-headedness.
Persistent dry cough primarily associated with telmisartan less common than ACE inhibitors.
Edema or swelling in ankles and feet related to vasodilatory effects.
Muscle weakness, cramping, and electrolyte disturbances from indapamide.
Serious allergic reactions including anaphylaxis and angioedema, though rare.
Electrolyte imbalances such as hypokalemia or hyponatremia due to diuretic action.
Visual disturbances including rare reports of eye pain or vision changes.
Potential worsening of renal function in susceptible patients.
Rare but serious hypotension-related syncope or fainting episodes.
Increased risk of fetal toxicity leading to injury or death if used during pregnancy.
Possible interactions causing elevated blood levels of concomitant drugs due to metabolic pathways.

Precautions

Avoid use in pregnancy due to risk of fetal harm or death.
Caution in patients with renal impairment or kidney function disturbances.
Monitor electrolytes closely to detect hypokalemia or hyponatremia.
Use with caution in elderly patients sensitive to blood pressure lowering effects.
Avoid dehydration as it may exacerbate hypotension and electrolyte loss.
Monitor for signs of angioedema or allergic hypersensitivity reactions.
Adjust dosage carefully in patients with hepatic impairment affecting drug metabolism.
Avoid concurrent use with aliskiren in diabetic patients due to risk of adverse renal effects.
Advise patients to report symptoms of muscle weakness or irregular heartbeat promptly.
Be cautious in patients with history of gout, as diuretics may increase uric acid levels.
Use cautiously in patients with glaucoma or those susceptible to acute myopia and choroidal effusion.
Avoid abrupt discontinuation to prevent rebound hypertension.
Use with care when combining with other antihypertensives to avoid excessive hypotension.
Ensure patients understand proper administration, including swallowing tablets whole.
Regular blood pressure monitoring and laboratory assessments are essential.

Warnings

Do not use Widaplik if pregnant; it causes fetal injury or death.
May cause symptomatic hypotension, particularly during initial therapy or dose escalations.
Avoid use in patients with anuria or severe renal impairment with little or no urine output.
Risk of severe allergic reactions including anaphylaxis and angioedema; discontinue immediately if these occur.
Avoid concomitant use with aliskiren in diabetes due to increased risk of renal impairment and hyperkalemia.
Serious electrolyte imbalances can occur, necessitating close monitoring.
Risk of dehydration leading to further hypotension and renal complications.
Patients experiencing vision loss or severe eye pain should seek immediate medical attention.
Potential interactions with drugs such as lithium, NSAIDs, digoxin, and immunosuppressants warrant caution.
In overdose, severe hypotension, dizziness, and electrolyte abnormalities may be life-threatening.
Widaplik may impair ability to perform tasks requiring mental alertness until individual response is known.
Use with caution in patients with heart failure or impaired ventricular function.
Monitor for changes in liver function tests during treatment.
Inform patients to avoid sudden position changes to reduce orthostatic hypotension risk.
Discontinue use immediately if pregnancy is detected.

Contraindication

Known hypersensitivity or allergy to telmisartan, amlodipine, indapamide, or related sulfonamide drugs.
Anuria or severe renal impairment with negligible urine production.
Pregnancy due to risk of fetal toxicity and death.
Concomitant use with aliskiren in patients with diabetes or renal impairment.
History of angioedema related to previous ARB or calcium channel blocker therapy.
Severe hepatic impairment or cholestasis affecting drug metabolism and elimination.
Hypersensitivity to any inactive ingredients in Widaplik formulation.
Patients with significant electrolyte disturbances untreated prior to initiation.
Severe hypotension or shock.
Concurrent use with other medications contraindicated with any component of Widaplik.
Uncontrolled arrhythmias or advanced sinoatrial block without pacemaker.
Breastfeeding mothers as safety in nursing infants is unknown.
Patients with severe aortic stenosis where vasodilation could be hazardous.
Known hypersensitivity to sulfonamide derivatives due to indapamide content.
Severe hyponatremia or hypokalemia at baseline.

Drug Interactions

Aliskiren increases risk of renal impairment and hyperkalemia; contraindicated with Widaplik in diabetics.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce antihypertensive effect and impair renal function.
Lithium levels may be elevated, increasing risk of toxicity.
Digoxin levels may be affected, necessitating monitoring.
Simvastatin co-administration requires caution due to potential pharmacokinetic interactions.
Immunosuppressants like cyclosporine and tacrolimus may increase risk of nephrotoxicity.
Concomitant use of other antihypertensives may potentiate hypotensive effects.
Drugs affecting potassium levels (e.g., potassium supplements, potassium-sparing diuretics) increase hyperkalemia risk.
CYP3A4 inhibitors or inducers may alter amlodipine metabolism and plasma concentrations.
Norepinephrine’s vasoconstrictive effects may be antagonized by Widaplik components.
Combination with other diuretics increases electrolyte disturbance risks.
Alcohol and CNS depressants may enhance hypotensive and sedative effects.
Concomitant use with other calcium channel blockers requires caution.
Medications prolonging QT interval warrant monitoring for potential cardiac effects.
Avoid grapefruit juice as it may increase amlodipine levels.

Preparations Of The Drug

Widaplik tablets containing fixed-dose combinations: 10 mg telmisartan / 1.25 mg amlodipine / 0.625 mg indapamide.
Higher strength tablets with 20 mg telmisartan / 2.5 mg amlodipine / 1.25 mg indapamide.
Maximum strength tablets with 40 mg telmisartan / 5 mg amlodipine / 2.5 mg indapamide.
Tablets are film-coated, intended for oral use only, to be swallowed whole without crushing or chewing.
Formulated with inactive excipients including croscarmellose sodium, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, polyvinyl pyrrolidone, pregelatinized starch, and sodium hydroxide for stability and bioavailability.
Packaged in original container to protect from moisture and light.
Stored at controlled room temperature between 20°C and 25°C (68°F to 77°F).
Available in blister packs or bottles depending on manufacturer and market.
Manufactured under GMP by Piramal Pharma Limited, India.
Distributed by George Medicines Pty Limited under registered trademark Widaplik.
Each tablet’s composition ensures consistent release and absorption of active ingredients.
Comprehensive patient information leaflet included with each preparation focusing on administration and safety.
Tablets designed for once-daily dosing convenience to improve compliance.
Available by prescription only with specific dosing regimens guided by clinical response.
Packaging designed to ensure potency and prevent accidental ingestion by children.